3.29
+0.32(+10.77%)
Currency In USD
| Previous Close | 2.97 |
| Open | 3.02 |
| Day High | 3.31 |
| Day Low | 2.98 |
| 52-Week High | 7.13 |
| 52-Week Low | 0.46 |
| Volume | 1.89M |
| Average Volume | 2.49M |
| Market Cap | 983.7M |
| PE | -5.87 |
| EPS | -0.56 |
| Moving Average 50 Days | 2.59 |
| Moving Average 200 Days | 1.71 |
| Change | 0.32 |
If you invested $1000 in ProKidney Corp. (PROK) since IPO date, it would be worth $325.42 as of October 21, 2025 at a share price of $3.29. Whereas If you bought $1000 worth of ProKidney Corp. (PROK) shares 3 years ago, it would be worth $320.35 as of October 21, 2025 at a share price of $3.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
GlobeNewswire Inc.
12 hours ago
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Comp
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
GlobeNewswire Inc.
Aug 27, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and